Placebo for IMP PTI-428 clinical trials

A Phase IIb, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Subjects with Cystic Fibrosis Aged 18 Years or Older (CHOICES)

This study is looking at new medications, Dirocaftor, Posenacaftor, and Nesolicaftor, for adults with Cystic Fibrosis. We want to see how well they improve breathing and if they are safe, comparing them to a dummy treatment.